Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bria-PROS+
- Development stage
- Preclinical
- Lead developer
- BriaCell Therapeutics
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intradermal
01
Overview
Bria-PROS+ is a next-generation, off-the-shelf, cell-based immunotherapy developed for the treatment of prostate cancer. It is designed to activate both innate and adaptive immune responses against tumor cells by expressing cancer antigens and modulating immune cell activity. The therapy stimulates helper T cells (CD4+), cytotoxic T cells (CD8+), natural killer (NK) cells, and NKT cells, enhancing their ability to recognize and kill prostate cancer cells. Engineered to express co-stimulatory molecules and immunomodulatory cytokines such as CD86, Interleukin 12, NKG2D ligand, and Granulocyte-macrophage colony-stimulating factor (GM-CSF), Bria-PROS+ aims to overcome tumor immune evasion mechanisms like HLA class I loss. The product is intended for personalized yet ready-to-use administration via intradermal injection in a physician’s office setting. Developed by BriaCell Therapeutics Corp., it is currently advancing toward clinical trials for prostate cancer[1][4][5][6][7][8].
- Brand names
- Bria-ProsBria-PROS+
- Other names
- Bria-PROS+™
02
Targets
CD28 (Cluster of Differentiation 28)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)IL-12R (Interleukin-12 receptor)NKG2D (Natural killer group 2 member D receptor)
Beyond the preview
Go deeper on Bria-PROS+.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bria-PROS+.